AURA

Dopo l'orario di chiusura: 8.91

Aura Biosciences Inc (AURA)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Aura Biosciences Inc Stock (AURA) Company Profile

Aura Biosciences Inc

(617)500-8864

80 GUEST STREET, BOSTON

Prossima data di guadagno

Ultimi documenti SEC

AURA's Discussions on Twitter

Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-07-27	Iniziato	Scotiabank	Sector Outperform
2023-04-17	Ripresa	BTIG Research	Buy
2022-07-19	Iniziato	JMP Securities	Mkt Outperform

Aura Biosciences Inc Borsa (AURA) Ultime notizie

Aura Biosciences Inc Azioni (AURA) Dati Finanziari

Aura Biosciences Inc (AURA)

Aura Biosciences Inc Stock (AURA) Company Profile

Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades

Aura Biosciences Inc Borsa (AURA) Ultime notizie

Where are the Opportunities in (AURA) - Stock Traders Daily

Ensign Peak Advisors Inc Sells 105,316 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat

Aura Biosciences names interim CFO as Julie Feder departs By Investing.com - Investing.com Australia

Aura Biosciences names interim CFO as Julie Feder departs - Investing.com

Wall Street SWOT: Aura Biosciences stock shows promise amid cancer treatment trials - Investing.com

Aura Biosciences Executives Transition and Compensation Update - TipRanks

Long Focus Capital Management LLC Has $7.99 Million Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat

Aura Energy (LON:AURA) Trading 11.1% Higher - MarketBeat

Bioxyne signs amendment with Aura Therapeutics to manufacture product volumes - Biotech Dispatch

Aurora Films to Go Public in Q4 2024 With Exclusive Token Issuance - EIN News

A Guide To The Risks Of Investing In Aurora Innovation Inc (AUR) - Knox Daily

Hancock Whitney Corp Makes New Investment in Acuity Brands, Inc. (NYSE:AYI) - Defense World

Financial Health Check: Examining Aurora Innovation Inc (AUR)’s Key Ratios - The Dwinnex

Should investors be concerned about Aurora Innovation Inc (AUR)? - US Post News

Bank of New York Mellon Corp Acquires 48,549 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World

Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + - Seeking Alpha

Aurora Innovation (NASDAQ:AUR) Hits New 52-Week High at $5.31 - MarketBeat

Aura Biosciences (NASDAQ:AURA) Stock Rating Upgraded by Evercore ISI - MarketBeat

Aura Biosciences (NASDAQ:AURA) Raised to Strong-Buy at Evercore ISI - Defense World

$200M Cash, 8.8% Dividend Yield w/ 450K oz Gold Target | Aura Minerals with Rodrigo Barbosa - The Deep Dive

Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 5.7% in August - Defense World

aura Launches a One-Hour At-Home Health Check, Going Far Beyond Standard Blood Work - Business Wire

NCR's Realty Giant Gaurs Group Plans IPO, CMD Reveals Timeline, Projects and Other Details - News18

Aura Biosciences: Highly Derisked Late Stage Eye Cancer Company (NASDAQ:AURA) - Seeking Alpha

Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat

Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at JMP Securities - MarketBeat

Aura Biosciences' (AURA) Buy Rating Reiterated at HC Wainwright - MarketBeat

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - Zacks Investment Research

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - Yahoo Finance

Aura Biosciences (NASDAQ:AURA) Shares Gap Up to $9.07 - MarketBeat

Aura Biosciences Touts Promising Data From Eye Cancer Candidate - Benzinga

Aura Biosciences Shares Jump in Premarket on Positive Phase 2 Ocular Cancer Treatment Results - MarketWatch

Lifesci Capital Comments on Aura Biosciences, Inc.'s Q3 2024 Earnings (NASDAQ:AURA) - MarketBeat

Aura reports promising results for ocular cancer therapy - Investing.com

Aura Biosciences’ Breakthrough in Choroidal Melanoma Treatment - TipRanks

Positive Phase II Bolsters Aura Bioscience’s Confidence in VDC-based Therapy for Ocular Melanomas - Genetic Engineering & Biotechnology News

Aura Biosciences Reports Positive Phase 2 End of Study - GlobeNewswire

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma - StockTitan

Aura Biosciences (NASDAQ:AURA) Lifted to Strong-Buy at Lifesci Capital - Defense World

Lifesci Capital Upgrades Aura Biosciences (NASDAQ:AURA) to Strong-Buy - MarketBeat

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely - Simply Wall St

Levin Capital Strategies L.P. Purchases 216,266 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat

We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate - Yahoo Finance

Aura Biosciences to Host a Urologic Oncology Investor Event - GlobeNewswire

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 - StockTitan

A look into Aura Biosciences Inc (AURA)’s deeper side - SETE News

(AURA) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Aura Biosciences (NASDAQ:AURA) Receives Market Outperform Rating from JMP Securities - Defense World

Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire

Aura Biosciences to Participate in Upcoming Investor Conferences - Marketscreener.com

Aura Biosciences to Participate in Upcoming Investor Conferences - StockTitan

Aura Biosciences Inc Azioni (AURA) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AURA